Saturday, December 11, 2021 12:32:40 PM
The reason they are refusing to release the data is because it is bad. That's right, the data is bad. I mean, could it not be more obvious? What else could they possibly be (not) doing to make people realize this is a failed trial, and that you can't change endpoints after conducting a trial for 16 years, and you can't use historical controls to make valid comparisons? It is a failure. That is why they haven't even bothered to update the trial register. Failure is BY FAR the most likely and plausible explanation for why we haven't seen the data.
They are waiting on certification for Sawston to announce it. That makes perfect sense. You don't want to announce the trial failed now, before you get certification, because everything could collapse. But if you wait until you have certification, then you have something to fall back on (at least for Advent) and it is highly unlikely that everything would collapse.
Unfortunately, when that happens, I think there's a good chance NWBO shareholders will be left on the sideline as Advent ramps up into a full-scale manufacturing operation - like Cognate did before it sold for $800 million. Believe me when I tell you that sale got her attention. When she saw that Cognate sold for $800 million just a couple years after she had sold it for a lot less, I think a light bulb went off in her head. She doesn't need this failed vaccine anymore, and she doesn't need NWBO shareholders anymore, either.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
FEATURED Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • Mar 16, 2026 8:37 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
